Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at ASH Annual Meeting

Corvus Pharmaceuticals will present final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma at the 67th American Society of Hematology Annual Meeting & Exposition. The oral presentation will take place on December 8, 2025, and will highlight the results of the trial. Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing soquelitinib, a selective interleukin-2-inducible T cell kinase inhibitor, for the treatment of relapsed/refractory T cell lymphomas.